RU2015119557A - Конъюгаты лекарственное вещество-белок - Google Patents
Конъюгаты лекарственное вещество-белок Download PDFInfo
- Publication number
- RU2015119557A RU2015119557A RU2015119557A RU2015119557A RU2015119557A RU 2015119557 A RU2015119557 A RU 2015119557A RU 2015119557 A RU2015119557 A RU 2015119557A RU 2015119557 A RU2015119557 A RU 2015119557A RU 2015119557 A RU2015119557 A RU 2015119557A
- Authority
- RU
- Russia
- Prior art keywords
- group
- conjugate
- conjugate according
- integer
- linker
- Prior art date
Links
- 102000023732 binding proteins Human genes 0.000 claims abstract 9
- 108091008324 binding proteins Proteins 0.000 claims abstract 9
- 125000005647 linker group Chemical group 0.000 claims abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 8
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims abstract 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract 3
- 229930126263 Maytansine Natural products 0.000 claims abstract 3
- 229940009098 aspartate Drugs 0.000 claims abstract 3
- 229930195712 glutamate Natural products 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000005977 Ethylene Substances 0.000 claims abstract 2
- 108091005804 Peptidases Proteins 0.000 claims abstract 2
- 239000004365 Protease Substances 0.000 claims abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 2
- 125000004450 alkenylene group Chemical group 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717743P | 2012-10-24 | 2012-10-24 | |
| US61/717,743 | 2012-10-24 | ||
| PCT/GB2013/052662 WO2014064424A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015119557A true RU2015119557A (ru) | 2016-12-20 |
Family
ID=49488609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015119557A RU2015119557A (ru) | 2012-10-24 | 2013-10-11 | Конъюгаты лекарственное вещество-белок |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20150283259A1 (enExample) |
| EP (1) | EP2911696B1 (enExample) |
| JP (1) | JP6328649B2 (enExample) |
| KR (1) | KR20150085808A (enExample) |
| CN (1) | CN104755106B (enExample) |
| AU (1) | AU2013336410B2 (enExample) |
| BR (1) | BR112015008311A2 (enExample) |
| CA (1) | CA2884359A1 (enExample) |
| DK (1) | DK2911696T3 (enExample) |
| ES (1) | ES2652513T3 (enExample) |
| HU (1) | HUE037604T2 (enExample) |
| IL (1) | IL237673A0 (enExample) |
| IN (1) | IN2015DN02577A (enExample) |
| MX (1) | MX2015005124A (enExample) |
| NO (1) | NO2789793T3 (enExample) |
| RU (1) | RU2015119557A (enExample) |
| SG (1) | SG11201501955VA (enExample) |
| WO (1) | WO2014064424A1 (enExample) |
| ZA (1) | ZA201501996B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022585B1 (pt) | 2013-03-15 | 2023-04-04 | Regeneron Pharmaceuticals, Inc | Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos |
| WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| JP6608823B2 (ja) | 2013-08-26 | 2019-11-20 | レゲネロン ファーマシューティカルス，インコーポレーテッド | マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用 |
| US10406198B2 (en) * | 2014-05-23 | 2019-09-10 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| US9951141B2 (en) | 2014-06-02 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates, their preparation and their therapeutic use |
| GB2531715A (en) * | 2014-10-24 | 2016-05-04 | Polytherics Ltd | Novel drug conjugates |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| CA2963043A1 (en) * | 2014-10-24 | 2016-04-28 | Polytherics Limited | Conjugates and conjugating reagents |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| US10509035B2 (en) * | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
| AU2017211120C1 (en) | 2016-01-25 | 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| JP7038663B2 (ja) | 2016-04-14 | 2022-03-18 | ポリセリックス・リミテッド | 環中に少なくとも２個の（－ｃｈ２－ｃｈ２－０－）単位を含むリンカーを含むコンジュゲート及びコンジュゲート試薬 |
| GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| ES2965349T3 (es) | 2016-06-06 | 2024-04-12 | Abzena Uk Ltd | Anticuerpos, usos de los mismos y conjugados de los mismos |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| GB201615725D0 (en) * | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| KR20220147720A (ko) | 2016-11-14 | 2022-11-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| PH12021553156A1 (en) | 2019-06-29 | 2022-07-25 | Hangzhou Dac Biotech Co Ltd | Conjugates of tubulysin derivatives and cell binding molecules and methods of making |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| JP2023540526A (ja) | 2020-09-04 | 2023-09-25 | ノヴァロック バイオセラピューティクス， リミテッド | ネクチン－４抗体およびそれの使用 |
| WO2022197945A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| CN117147824A (zh) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | 一种抗体缀合物及其应用 |
| WO2024260217A1 (zh) * | 2023-06-19 | 2024-12-26 | 广东菲鹏生物有限公司 | 标记Fab抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| SG149815A1 (en) * | 2003-11-06 | 2009-02-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| NZ566982A (en) * | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
| SI2211904T1 (sl) * | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| BRPI0911442A2 (pt) * | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| WO2010100430A1 (en) | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| US20150125473A1 (en) * | 2012-06-19 | 2015-05-07 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
-
2012
- 2012-04-24 NO NO14172620A patent/NO2789793T3/no unknown
-
2013
- 2013-10-11 KR KR1020157009803A patent/KR20150085808A/ko not_active Withdrawn
- 2013-10-11 DK DK13783360.4T patent/DK2911696T3/en active
- 2013-10-11 EP EP13783360.4A patent/EP2911696B1/en active Active
- 2013-10-11 ES ES13783360.4T patent/ES2652513T3/es active Active
- 2013-10-11 MX MX2015005124A patent/MX2015005124A/es unknown
- 2013-10-11 CA CA2884359A patent/CA2884359A1/en not_active Abandoned
- 2013-10-11 HU HUE13783360A patent/HUE037604T2/hu unknown
- 2013-10-11 SG SG11201501955VA patent/SG11201501955VA/en unknown
- 2013-10-11 BR BR112015008311A patent/BR112015008311A2/pt not_active Application Discontinuation
- 2013-10-11 AU AU2013336410A patent/AU2013336410B2/en active Active
- 2013-10-11 IN IN2577DEN2015 patent/IN2015DN02577A/en unknown
- 2013-10-11 US US14/437,571 patent/US20150283259A1/en not_active Abandoned
- 2013-10-11 JP JP2015538561A patent/JP6328649B2/ja active Active
- 2013-10-11 RU RU2015119557A patent/RU2015119557A/ru not_active Application Discontinuation
- 2013-10-11 WO PCT/GB2013/052662 patent/WO2014064424A1/en not_active Ceased
- 2013-10-11 CN CN201380055945.7A patent/CN104755106B/zh active Active
-
2015
- 2015-03-11 IL IL237673A patent/IL237673A0/en unknown
- 2015-03-23 ZA ZA2015/01996A patent/ZA201501996B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2911696B1 (en) | 2017-09-20 |
| CN104755106B (zh) | 2018-03-13 |
| AU2013336410A1 (en) | 2015-04-09 |
| HUE037604T2 (hu) | 2018-09-28 |
| US20150283259A1 (en) | 2015-10-08 |
| ZA201501996B (en) | 2016-01-27 |
| NO2789793T3 (enExample) | 2018-01-27 |
| JP2015536329A (ja) | 2015-12-21 |
| HK1208186A1 (en) | 2016-02-26 |
| KR20150085808A (ko) | 2015-07-24 |
| ES2652513T3 (es) | 2018-02-02 |
| CN104755106A (zh) | 2015-07-01 |
| SG11201501955VA (en) | 2015-04-29 |
| AU2013336410B2 (en) | 2017-08-03 |
| WO2014064424A1 (en) | 2014-05-01 |
| DK2911696T3 (en) | 2018-01-08 |
| IN2015DN02577A (enExample) | 2015-09-11 |
| IL237673A0 (en) | 2015-04-30 |
| EP2911696A1 (en) | 2015-09-02 |
| JP6328649B2 (ja) | 2018-05-23 |
| MX2015005124A (es) | 2015-10-29 |
| BR112015008311A2 (pt) | 2017-07-04 |
| CA2884359A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| WO2023078021A1 (en) | Bcma monoclonal antibody and the antibody-drug conjugate | |
| RU2476441C2 (ru) | Cd19-связывающие средства и их применение | |
| RU2014128467A (ru) | Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
| RU2016111131A (ru) | Способы конъюгации сайт-специфических антител и композиции | |
| RU2014124984A (ru) | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы | |
| RU2009132006A (ru) | Антитела и содержащие их фармацевтические композиции, подходящие для ингибирования активности металлопротеинов | |
| RU2010102044A (ru) | Конъюгаты, содержащие гидрофильные спейсеры линкеров | |
| AR048098A1 (es) | Conjugados de caliqueamicina | |
| RU2016111137A (ru) | Сконструированные конъюгаты против dll3 и способы применения | |
| RU2016139340A (ru) | Коньюгаты "антитело - лекарственное средство" с высокой лекарственной нагрузкой | |
| RU2755728C2 (ru) | Новый конъюгат аманитина | |
| RU2015101332A (ru) | Новые реагенты для конъюгации | |
| RU2015112025A (ru) | Новое соединение с эффектами тромболизиса, акцептирования свободных радикалов и направленного действия на тромб, а также способ его получения и применение | |
| RU2018136778A (ru) | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы | |
| JP2017537893A5 (enExample) | ||
| AR111481A1 (es) | Sistemas de entrega de liberación sostenida que comprenden enlazadores no rastreables | |
| JP2016531915A5 (enExample) | ||
| RU2019134399A (ru) | Конъюгат анти-trop2 антитело-лекарственное средство | |
| UA117294C2 (uk) | Імунокон'югат | |
| RU2019122802A (ru) | Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы | |
| HRP20200032T1 (hr) | Antitijelo lijek konjugati |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161012 |